16:29 , May 4, 2018 |  BC Week In Review  |  Clinical News

uniQure reports preclinical data for Huntington's disease candidate

uniQure N.V. (NASDAQ:QURE) reported preclinical data showing that AMT-130 decreased mutant huntingtin (HTT) protein in animal models of Huntington's disease. Data were presented at the American Academy of Neurology meeting in Los Angeles. In a...
16:17 , May 4, 2018 |  BC Week In Review  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million on May 3 in a follow-on through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright &...
17:21 , May 3, 2018 |  BC Extra  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million in a follow-on Thursday through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright & Co. and...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR...